2022
Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer
Saeed N, Jin L, Amini A, Verma V, Lester-Coll N, Chen P, Decker R, Park H. Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer. American Journal Of Clinical Oncology 2022, 46: 66-72. PMID: 36662872, DOI: 10.1097/coc.0000000000000974.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage I non-small cell lung cancerOverall survivalCell lung cancerLung cancerStereotactic body radiation therapyNational Cancer DatabaseLog-rank testBody radiation therapyOptimal fractionation scheduleMultivariable modeling techniquesOS benefitHypofractionated radiotherapySurvival impactMultivariable analysisCox regressionCancer DatabaseRetrospective analysisFractionation schedulesRadiation therapyHFRTPatientsCFRTRadiotherapyKaplan-Meier estimator
2021
Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial
Liu Y, Cheng Y, Li K, Shi J, Liu Y, Wu L, Han B, Chen G, He J, Wang J, Qin H, Li X, Hamaji M, Park HS. Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial. Translational Lung Cancer Research 2021, 10: 3793-3806. PMID: 34733629, PMCID: PMC8512470, DOI: 10.21037/tlcr-21-632.Peer-Reviewed Original ResearchDisease control rateProgression-free survivalObjective response rateSmall cell lung cancerOverall survivalThoracic radiotherapySubgroup analysisRT subgroupPlacebo-controlled phase 2 trialSmall cell lung cancer patientsCell lung cancer patientsPrevious thoracic radiotherapyPrior thoracic radiotherapyRelapsed SCLC patientsPhase 2 trialCell lung cancerLung cancer patientsOS benefitPFS benefitSCLC patientsPlacebo groupPlacebo armRT patientsCancer patientsControl rate
2020
Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials
Pathak R, De Lima Lopes G, Yu H, Aryal MR, Ji W, Frumento KS, Wallis CJD, Klaassen Z, Park HS, Goldberg SB. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials. Cancer 2020, 127: 709-719. PMID: 33119177, DOI: 10.1002/cncr.33269.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerSingle-agent ICICell lung cancerPD-L1Lung cancerAdditional overall survival benefitsEfficacy of chemoimmunotherapyFirst-line ICIHigh PD-L1Overall survival benefitCochrane Central RegisterFirst-line treatmentPD-L1 statusPhase 3 trialLow PD-L1Absence of headSignificant differencesRandom-effects modelBayesian random-effects modelImproved PFSOS benefitEfficacy outcomesEligible trialsCentral RegisterComparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Pathak R, Lopes G, Yu H, Ji W, Aryal M, Frumento K, Wallis C, Klaassen Z, Park H, Goldberg S. Comparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis. Journal Of Clinical Oncology 2020, 38: 9552-9552. DOI: 10.1200/jco.2020.38.15_suppl.9552.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsIpi/nivoPD-1 axis inhibitorsPD-L1 1Phase 3 RCTsPD-L1 statusPD-L1Advanced non-small cell lung cancerSingle-agent immune checkpoint inhibitorsSystematic reviewCombination immune checkpoint inhibitorsNon-small cell lung cancerDual checkpoint blockadeCTLA-4 inhibitorsFront-line treatmentCell lung cancerSignificant differencesAdvanced NSCLCICI monotherapyOS benefitCheckpoint inhibitorsProspective trialCheckpoint blockadeCombination chemotherapyNSCLC patientsAssociation of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.
Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, Sprenkle P, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaCytoreductive nephrectomyICI eraImproved overall survivalNational Cancer DatabaseOverall survivalIFN eraFuhrman gradeBenefit of CNEfficacy of ICIsClinical T stageCox regression analysisTreatment facility typeRenal cell carcinomaCARMENA trialInterferon eraMultivariable associateN0 diseaseOS benefitProspective reevaluationMedian ageT stageCell carcinomaCancer DatabasePartial nephrectomy
2017
Post-operative radiotherapy is associated with improved survival in esophageal cancer with positive surgical margins
Gao SJ, Park HS, Corso CD, Rutter CE, Khan SA, Johung KL. Post-operative radiotherapy is associated with improved survival in esophageal cancer with positive surgical margins. Journal Of Gastrointestinal Oncology 2017, 8: 953-961. PMID: 29299354, PMCID: PMC5750177, DOI: 10.21037/jgo.2017.08.12.Peer-Reviewed Original ResearchPost-operative radiotherapyClinical stage INational Cancer Data BaseEarly-stage esophageal cancerOverall survivalPositive surgical marginsPositive marginsUpfront esophagectomyEsophageal cancerStage IImproved survivalSurgical marginsMultivariable Cox regression analysisImproved overall survivalReceipt of chemotherapyCox regression analysisMultivariable logistic regressionEsophageal cancer patientsLog-rank testAdjuvant chemotherapyOS benefitPostoperative chemotherapyPN0 diseaseMultivariable analysisCancer patients
2016
Who benefits from chemoradiation in stage III–IVA endometrial cancer? An analysis of the National Cancer Data Base
Lester-Coll NH, Park HS, Rutter CE, Corso CD, Young MR, Ratner ES, Litkouhi B, Decker RH, Yu JB, Damast S. Who benefits from chemoradiation in stage III–IVA endometrial cancer? An analysis of the National Cancer Data Base. Gynecologic Oncology 2016, 142: 54-61. PMID: 27151429, DOI: 10.1016/j.ygyno.2016.04.544.Peer-Reviewed Original ResearchConceptsAdvanced endometrial cancerImproved overall survivalNational Cancer Data BaseOverall survivalHistologic gradeEndometrial cancerCox proportional hazards regressionPropensity scoreMultivariable subgroup analysisSignificant OS benefitGrade 1 patientsProportional hazards regressionKaplan-Meier estimatesLog-rank testLack of benefitOS benefitAdjuvant therapyStage IIIAStage IVAFIGO stageAdjuvant CRTHazards regressionTumor sizeRegional radiotherapySubgroup analysisConcurrent chemoradiotherapy versus radiotherapy alone for “biopsy‐only” glioblastoma multiforme
Kole AJ, Park HS, Yeboa DN, Rutter CE, Corso CD, Aneja S, Lester-Coll NH, Mancini BR, Knisely JP, Yu JB. Concurrent chemoradiotherapy versus radiotherapy alone for “biopsy‐only” glioblastoma multiforme. Cancer 2016, 122: 2364-2370. PMID: 27172136, DOI: 10.1002/cncr.30063.Peer-Reviewed Original ResearchConceptsPropensity score-matched analysisConcurrent chemoradiotherapySignificant OS benefitOverall survivalGlioblastoma multiformeOS benefitUS National Cancer Data BaseMultivariable Cox proportional hazards regressionNational Cancer Data BaseCox proportional hazards regressionImproved overall survivalStandard postoperative therapyProportional hazards regressionMultivariable logistic regressionLog-rank testStandard of careChi-square testClinicopathologic predictorsPostoperative therapySurgical resectionImproved survivalMedian ageMultivariable analysisHazards regressionNational cohort